This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
6, 2025 Medtronic plc hasannounced it received CE ( Conformit Europenne ) Mark for the Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heartdisease patients with native or surgically repaired right ventricular outflow tract (RVOT).
BackgroundCoronary heartdisease (CHD) is a pervasive chronic condition that poses a significant threat to global health and mortality worldwide. The control group underwent a standard rehabilitation program, while the intervention group participated in an individualized exercise rehabilitation program.
Background:Neonates with complex congenital heartdisease and pulmonary overcirculation have been historically treated surgically. Pulmonary arteries grew adequately for age, and devices were easily removed without complications. However, subcohorts may benefit from less invasive procedures. kilograms [IQR, 2.1–3.3])
Congenital heartdisease (CHD) is likely to increase vulnerability and understanding the predictors of adverse outcomes is key to optimising care. Methods Multicentre UK study undertaken 1 March 2020–30 June 2021 during the COVID-19 pandemic. to 7.97 (p=0.01)) and genetic disease (OR 2.87, 95% CI 1.04
Meanwhile, traditional methods for cardiac detection still rely on reactive, symptom-driven interventions that often catch heartdisease too late, when treatment is complex, critical and costly. AI-enabled remote cardiac monitoring is is already revolutionizing how we detect, diagnose, mitigate and manage heart conditions.
Cardiovascular diseases, particularly coronary heartdisease (CHD), have become an epidemic in India. In such scenarios, cardiologists’ primary form of treatment for children with coronary heartdisease is a heart valve implant. Shockingly, 9 out of every 1000 newborns are diagnosed with CHD annually.
This certification is known to be one of the harder ones, with a pass rate of 88% in 2021 , so don’t procrastinate studying. The exam covers the following topics: Arrhythmias 15% Coronary Artery Disease 21.5% Your Cardiology MOC exam is coming up, have you started preparing?
have PAD, which increases the risk of amputation, heart attack, stroke and death. Among those ages 65 and older, nearly 50% who underwent limb amputation died within one year after surgery, according to the 2024 HeartDisease and Stroke Statistics: A Report of U.S. and Global Data From the American Heart Association.
The Cardiovascular Disease Maintenance of Certification Exam can be difficult, with a pass rate in 2021 of 88%. The Cardiology MOC exam covers the following subjects : Arrhythmias 15% Coronary Artery Disease 21.5% Pulmonary Circulation Disorders 3% Systemic Disorders Affecting the Circulatory System 7% How is the exam scored?
Methods This was a retrospective analysis of the Verona Valvular HeartDisease Registry (Italy) including 250 patients (83 (80–86) years, 53% female) with severe AS who underwent TAVI between 2019 and 2021. The primary endpoint was the composite of cardiovascular death and rehospitalisation for heart failure (HF).
ABSTRACT Aims The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non-CV, in a large real-world heart failure (HF) population across the ejection fraction (EF). Methods and Results Patients with HF from the Swedish HF Registry between 2000-2021 were included.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)
Methods and ResultsThere were 5576 patients enrolled in the Swedish HF registry between 2017 and 2021 and included in the study; 21% had EF 60%, 5% EF 65%, and 1.5% We characterized EF distribution, characteristics, and outcomes in patients with HF and EF 50%.Methods
In pregnant women with significant heartdisease : A quick LSCS or a potentially prolonged natural delivery,which is more safe ? For women with significant heartdisease (e.g., In women with significant heartdisease, the physiological demands of labor (e.g., 2021 Apr 13;77(14):1799-1812. 2021.01.057.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content